{"id":"W4403086466","doi":"10.1016/j.ebiom.2024.105322","title":"Insights into the use of biomarkers in clinical trials in Alzheimer's disease","year":2024,"lang":"en","type":"review","venue":"EBioMedicine","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"Instituto de Salud Carlos III; Fonds de Recherche du Québec - Santé; Horizon 2020 Framework Programme; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas; Instituto Serrapilheira; Fundación Tatiana Pérez de Guzmán el Bueno; Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul; Conselho Nacional de Desenvolvimento Científico e Tecnológico; National Institutes of Health; Generalitat de Catalunya; Instituto Nacional de Ciência e Tecnologia para Excitotoxicidade e Neuroproteção; European Regional Development Fund; European Commission; Alzheimer's Association","keywords":"Alzheimer's disease; Clinical trial; Disease; Medicine; Bioinformatics; MEDLINE; Biology; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01587077,0.001017403,0.002338532,0.004537079,0.0003610088,0.002928525,0.001291762,0.002361966,0.002793221],"category_scores_gemma":[0.02208991,0.0005736918,0.001546816,0.005134528,0.002000661,0.003217678,0.001584645,0.003283189,0.000903075],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001894667,"about_ca_system_score_gemma":0.003898913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001319925,"about_ca_topic_score_gemma":0.002363661,"domain_scores_codex":[0.991548,0.005060744,0.001278131,0.0005182327,0.001407089,0.0001879012],"domain_scores_gemma":[0.9722596,0.02462118,0.001320379,0.0003537725,0.001283006,0.0001621231],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009032253,0.00004713156,0.0002736751,0.0683528,0.0003457902,0.0001461321,0.000528231,0.0005952078,0.0006470935,0.0360344,0.007997757,0.8849416],"study_design_scores_gemma":[0.00005840898,0.0001892695,0.001640723,0.1001319,0.0006633218,0.001032662,0.0003097866,0.0002855121,0.0005400193,0.02227557,0.8728257,0.00004711451],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00006731595,0.9977064,0.0005914403,0.0006146063,0.00007495598,0.00001647011,0.00001522155,0.000004197692,0.0009093666],"genre_scores_gemma":[0.001853366,0.9953932,0.00170495,0.0006741524,0.0001212679,0.00005565987,0.00001990292,0.00000345731,0.0001741053],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01587077,"threshold_uncertainty_score":0.08393371,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3710072076126499,"score_gpt":0.5215455738818651,"score_spread":0.1505383662692151,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}